Compare SSTK & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SSTK | COLL |
|---|---|---|
| Founded | 2003 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 675.2M | 1.5B |
| IPO Year | 2012 | 2015 |
| Metric | SSTK | COLL |
|---|---|---|
| Price | $18.44 | $49.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $25.00 | ★ $47.50 |
| AVG Volume (30 Days) | 279.2K | ★ 488.1K |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | ★ 7.22% | N/A |
| EPS Growth | ★ 66.87 | N/A |
| EPS | ★ 1.69 | 1.63 |
| Revenue | ★ $1,020,010,000.00 | $757,067,000.00 |
| Revenue This Year | $11.41 | $26.35 |
| Revenue Next Year | N/A | $3.67 |
| P/E Ratio | ★ $10.84 | $30.66 |
| Revenue Growth | 13.06 | ★ 26.34 |
| 52 Week Low | $14.35 | $23.23 |
| 52 Week High | $38.80 | $50.01 |
| Indicator | SSTK | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 40.19 | 70.68 |
| Support Level | $18.22 | $48.50 |
| Resistance Level | $19.16 | $49.92 |
| Average True Range (ATR) | 0.68 | 1.30 |
| MACD | 0.06 | -0.22 |
| Stochastic Oscillator | 25.51 | 93.78 |
Shutterstock Inc is a U.S.-based company that is engaged in the provision of digital content. The content segment, whose offerings include licenses for Images, Footage, Music, 3 Dimensional, and Generative AI content. Data, Distribution, and Service offerings address customer demand for products and services that are beyond its Content licenses. The company generates the majority of its revenue from Content offerings. Geographically the company generates the majority of its revenue from the Domestic market, but also has its presence in Europe and Rest of the Countries.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.